October 23, 2015 : Episode 1

Video

Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More

Related Videos
Justin M. Watts, MD
Marc-Oliver Grimm, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Hannah Choe, MD, an expert on GVHD
Related Content
Mark R. Litzow, MD
July 24th 2024

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Iopofosine I 131 in Waldenström Macroglobulinemia: © vitanovski - stock.adobe.com
July 23rd 2024

Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Justin M. Watts, MD
July 22nd 2024

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

Michal Taszner, MD
July 17th 2024

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma